Boston Scientific Corp

Company facts

Industry

Surgical & Medical Instruments & Apparatus

Headquarters

Marlborough, Massachusetts

Most recent report

8-K, filed Sep 8, 2026

Incorporated

Delaware

Filings on record

1,001+ filings

On EDGAR

CIK 885725

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Jun 2026 10-Q

SECSift found 3 of 11 sections worth reading, with 2 positive, 8 notable, and 2 negative flags.

• Financial Statements (Item 1)

  Massive deals (Penumbra $14.5B, MiRus $1.6B), $2B buyback, new restructuring, litigation updates.
  Positive

  • Appeals court reversed prior $42M verdict, finding UT’s patent invalid and not infringed, removing that liability.
  • Board boosted buyback authorization to $5B, and the company executed a $2B accelerated repurchase in Q2 2026.
  Notable

  • Pending acquisition of Penumbra for ~$14.5B; FTC second request received, stockholder vote passed, closing expected H2 2026.
  • Commercial paper outstanding jumped to $1.689B from zero at Dec 2025, short-term debt increased to fund operations.
  • New restructuring program approved July 2026; expects $700-800M pre-tax charges and $500M annual cost savings.
  Negative

  • If Boston Sci fails to exercise TAVR option, 75% of its $1.6B MiRus equity stake will be forfeited.

• Management's Discussion (Item 2)

  Full MD&A: revenue growth, margin, Penumbra deal, buyback, tax benefit, new restructuring.
  Notable

  • New global restructuring program approved July 21, 2026; no charge yet in Q2.
  • Q1 2026 discrete tax benefit of $384M from change in expected future tax rate on capitalized expenses.
  • $2B accelerated share repurchase executed in Q2 2026; $3B remaining under $5B authorization.
  Negative

  • Cash and equivalents fell to $539M at June 30, 2026 from $1,453M at March 31, 2026 (buyback and investing).

• Market Risk (Item 3)

  Fixed-rate debt dropped from ~100% to 87%, a real shift in risk profile.
  Notable

  • Currency derivative notional rose to $14.384B at June 30, 2026 from $12.726B at Dec 31, 2025.
  • Fixed-rate debt dropped from ~100% at Q1 2026 to 87% at Q2 2026, adding variable-rate exposure.

What changed: Jun 2026 vs. Mar 2026

About 19% of BSX's Jun 2026 10-Q is new information. 63 paragraphs were added, 147 changed, and 31 removed. Below are the most important lines SECSift identified.

• Item 1 83
• Item 2 54
• Item 6 3
• Item 3 2
• Item 4 2
• Item 5 1